OJEMDA™ (tovorafenib): Business overview

OJEMDA™ (tovorafenib) is a targeted therapy developed by Day One Biopharmaceuticals aimed at treating pediatric low-grade gliomas (pLGG) and other cancers. It represents a significant advancement in drug development, focusing on providing effective treatment options for patients of all ages with life-threatening diseases.